选择性5-羟色胺再摄取抑制剂用于行体外受精联合胚胎移植术的抑郁症妇女妊娠安全性的系统评价

发布时间：2019-07-04 21:41

【摘要】：目的:系统评价选择性5-羟色胺再摄取抑制剂(SSRI)用于行体外受精联合胚胎移植术的抑郁症妇女的妊娠安全性,为临床提供循证参考。方法:计算机检索PubMed、EMBase、Cochrane图书馆、Medline、中国生物医学文献数据库、相关期刊论文、中文科技期刊数据库和万方数据库,纳入SSRI(试验组)对比不接受药物或仅使用安慰剂(对照组)用于行体外受精联合胚胎移植术的抑郁症妇女的试验,提取资料并评价质量后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入4项研究,合计2 122例患者。Meta分析结果显示,两组患者流产率[RR=0.90,95%CI(0.61,1.35),P=0.62]、受孕率[RR=1.03,95%CI(0.73,1.45),P=0.87]和胎儿出生率[RR=1.03,95%CI(0.65,1.63),P=0.91]比较,差异均无统计学意义。结论:SSRI用于行体外受精联合胚胎移植术的抑郁症妇女不会增加流产率,对受孕率和胎儿出生率亦无显著影响。
[Abstract]:Objective: to systematically evaluate the pregnancy safety of depressed women undergoing in vitro fertilisation and embryo transfer with selective serotonin reuptake inhibitor (SSRI), and to provide evidence-based reference for clinical practice. Methods: PubMed,EMBase,Cochrane Library, Medline, Chinese Biomedical Literature Database, Chinese Journal full-text Database, Chinese Sci-tech Journal Database and Wanfang Database were searched by computer. SSRI (experimental group) was used to compare depressed women who did not receive drugs or only placebo (control group). After extracting the data and evaluating the quality, Meta analysis was carried out with Rev Man 5.3 statistical software. Results: a total of 2122 patients were included in four studies. Meta-analysis showed that there was no significant difference in abortion rate [RR=0.90,95%CI (0.61, 1.35), P 鈮，

本文编号：2510252